Abstract
The present clinical trial analyzed the safety of gene therapy using plasmidial constructs expressing vascular endothelial and hepatocyte growth factors in patients with critical limb ischemia. The study included 43 patients: 29 in the treatment group and 14 allocated to the placebo group. The primary end points were the rate of major amputations and the clinical safety of the method. Secondary end points were improvement of pain at rest, walking ability and the ankle/brachial pressure index. The overall major amputation rate was 31.04% in the treatment group and 71.42% in the placebo group (p=0.029). Pain at rest was improved in 65% of patients in the gene therapy group and in 7% in the placebo group (p=0.0006). There were no significant adverse effects in the treatment group. Conclusion: Gene therapy with vascular endothelial and hepatocyte growth factors is therapeutically safe and reduces the rate of major amputations and relieves pain at rest in patients with critical limb ischemia.
Keywords: Gene therapy, VEGF, HGF, critical limb ischemia, vascular endothelial, hepatocyte, ischemia, peripheral arterial, analgesics, narcotics, Leriche-Fontaine, PAOD, Therapeutic
Current Neurovascular Research
Title: Safety of Vascular Endothelial and Hepatocyte Growth Factor Gene Therapy in Patients with Critical Limb Ischemia
Volume: 8 Issue: 3
Author(s): Andrei Anghel, Georgel Taranu, Edward Seclaman, Andreea Rata, Liviu Tamas, Horatiu Moldovan, Sorin Ursoniu, Corina Samoila, Mihai Ionac and Aurel Popa-Wagner
Affiliation:
Keywords: Gene therapy, VEGF, HGF, critical limb ischemia, vascular endothelial, hepatocyte, ischemia, peripheral arterial, analgesics, narcotics, Leriche-Fontaine, PAOD, Therapeutic
Abstract: The present clinical trial analyzed the safety of gene therapy using plasmidial constructs expressing vascular endothelial and hepatocyte growth factors in patients with critical limb ischemia. The study included 43 patients: 29 in the treatment group and 14 allocated to the placebo group. The primary end points were the rate of major amputations and the clinical safety of the method. Secondary end points were improvement of pain at rest, walking ability and the ankle/brachial pressure index. The overall major amputation rate was 31.04% in the treatment group and 71.42% in the placebo group (p=0.029). Pain at rest was improved in 65% of patients in the gene therapy group and in 7% in the placebo group (p=0.0006). There were no significant adverse effects in the treatment group. Conclusion: Gene therapy with vascular endothelial and hepatocyte growth factors is therapeutically safe and reduces the rate of major amputations and relieves pain at rest in patients with critical limb ischemia.
Export Options
About this article
Cite this article as:
Anghel Andrei, Taranu Georgel, Seclaman Edward, Rata Andreea, Tamas Liviu, Moldovan Horatiu, Ursoniu Sorin, Samoila Corina, Ionac Mihai and Popa-Wagner Aurel, Safety of Vascular Endothelial and Hepatocyte Growth Factor Gene Therapy in Patients with Critical Limb Ischemia, Current Neurovascular Research 2011; 8 (3) . https://dx.doi.org/10.2174/156720211796558050
DOI https://dx.doi.org/10.2174/156720211796558050 |
Print ISSN 1567-2026 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5739 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Atheroprotective Properties of Pigment Epithelium-Derived Factor (PEDF) in Cardiometabolic Disorders
Current Pharmaceutical Design Dehydroepiandrosterone, Dehydroepiandrosterone Sulfate and Related Steroids: Their Role in Inflammatory, Allergic and Immunological Disorders
Current Drug Targets - Inflammation & Allergy Anti-Oxidant Gene Therapy by NFkB Decoy Oligodeoxynucleotide
Current Pharmaceutical Biotechnology Recent Patents in Imaging of the Vulnerable Atherosclerotic Plaque: The Search for the Holy Grail
Recent Patents on Medical Imaging East Meets West in the Search for Alzheimers Therapeutics - Novel Dimeric Inhibitors from Tacrine and Huperzine A
Current Alzheimer Research Anti-Atherosclerotic Therapy Based on Botanicals
Recent Patents on Cardiovascular Drug Discovery Gene Polymorphism of Angiotensin II Type 1 and Type 2 Receptors
Current Pharmaceutical Design The Role of microRNA in Ischemic and Hemorrhagic Stroke
Current Drug Delivery Disruption of Circadian Rhythms and Sleep in Critical Illness: Potential Implications for Angiogenesis After Myocardial Infarction. A Review
Current Pharmaceutical Design Impact of Red Wine Consumption on Cardiovascular Health
Current Medicinal Chemistry Highlighting the Protective or Degenerative Role of AMPK Activators in Dementia Experimental Models
CNS & Neurological Disorders - Drug Targets Endothelial Activation. Sliding Door to Atherosclerosis
Current Pharmaceutical Design Is the Therapeutic Potential of Stem Cells for Myocardial Regeneration Limited by Proarrhythmic Effects?
Current Cardiology Reviews Pathophysiological Implications of Dipeptidyl Peptidases
Current Protein & Peptide Science Brain Adaptation to Stressful Stimuli: A New Perspective on Potential Therapeutic Approaches Based on BDNF and NMDA Receptors
CNS & Neurological Disorders - Drug Targets Scientific Basis for the Use of Indian Ayurvedic Medicinal Plants in the Treatment of Neurodegenerative Disorders: 1. Ashwagandha
Central Nervous System Agents in Medicinal Chemistry Anthocyanins As Modulators of Cell Redox-Dependent Pathways in Non-Communicable Diseases
Current Medicinal Chemistry Stress, Cardiovascular Diseases and Surgery-Induced Angiogenesis
Current Angiogenesis (Discontinued) Research Strategies for Pain in Lumbar Radiculopathy Focusing on Acid-Sensing Ion Channels and Their Toxins
Current Topics in Medicinal Chemistry Neuroprotection of Dietary Virgin Olive Oil on Brain Lipidomics During Stroke
Current Neurovascular Research